Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.

It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.

The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies.

Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.